Avalo Therapeutics 관리

관리 기준 확인 2/4

Avalo Therapeutics CEO는 Garry Neil, Feb2022 에 임명되었습니다 의 임기는 2.75 년입니다. 총 연간 보상은 $ 1.08M, 44.2% 로 구성됩니다. 44.2% 급여 및 55.8% 보너스(회사 주식 및 옵션 포함). 는 € 539.48 가치에 해당하는 회사 주식의 0.001% 직접 소유합니다. 539.48. 경영진과 이사회의 평균 재임 기간은 각각 2.8 년과 2.7 년입니다.

주요 정보

Garry Neil

최고 경영자

US$1.1m

총 보상

CEO 급여 비율	44.2%
CEO 임기	2.8yrs
CEO 소유권	0.0005%
경영진 평균 재임 기간	2.8yrs
이사회 평균 재임 기간	2.7yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Garry Neil 의 보수는 Avalo Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$8m
Jun 30 2024	n/a	n/a	-US$19m
Mar 31 2024	n/a	n/a	-US$49m
Dec 31 2023	US$1m	US$475k	-US$32m
Sep 30 2023	n/a	n/a	-US$33m
Jun 30 2023	n/a	n/a	-US$25m
Mar 31 2023	n/a	n/a	-US$30m
Dec 31 2022	US$1m	US$469k	-US$42m
Sep 30 2022	n/a	n/a	-US$51m
Jun 30 2022	n/a	n/a	-US$72m
Mar 31 2022	n/a	n/a	-US$76m
Dec 31 2021	US$1m	US$423k	-US$84m
Sep 30 2021	n/a	n/a	-US$81m
Jun 30 2021	n/a	n/a	-US$77m
Mar 31 2021	n/a	n/a	-US$73m
Dec 31 2020	US$3m	US$373k	-US$64m

보상 대 시장: Garry 의 총 보상 ($USD 1.08M )은 German 시장( $USD 471.55K ).

보상과 수익: Garry 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Garry Neil (70 yo)

2.8yrs

테뉴어

US$1,075,362

보상

Dr. Garry A. Neil, M.D., serves as the Member of Scientific Advisory Board of Rapafusyn Research And Development, Inc. Dr. Garry serves as Independent Director of Celldex Therapeutics, Inc. since June 16,...

리더십 팀

이름	위치	테뉴어	보상	소유권
Garry Neil	Chairman of the Board	2.8yrs	US$1.08m	0.00053% € 539.5
Christopher Sullivan	CFO & Head of Investor relations	2.8yrs	US$607.65k	0.000050% € 50.9
Solomon Snyder	Founder and Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Barbara Slusher	Founder and Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Paul Varki	Chief Legal Officer	less than a year	데이터 없음	데이터 없음
Lisa Hegg	Senior Vice President of Program Management	2.8yrs	데이터 없음	데이터 없음
Colleen Matkowski	Senior Vice President of Global Regulatory Affairs & Quality Assurance	2.8yrs	데이터 없음	데이터 없음
Dino Miano	Senior Vice President of CMC & Technical Operations	2.8yrs	데이터 없음	데이터 없음
Mittie Doyle	Chief Medical Officer	less than a year	데이터 없음	데이터 없음

2.8yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 관리: C6K0 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Garry Neil	Chairman of the Board	2.4yrs	US$1.08m	0.00053% € 539.5
Solomon Snyder	Founder and Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Barbara Slusher	Founder and Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Sol Barer	Special Advisor & Strategic Advisory Board	3.4yrs	US$133.94k	데이터 없음
Gilla Kaplan	Independent Director	4.1yrs	US$60.12k	0% € 0
Ronald Borchardt	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Robert Lenox	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Anne Young	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Dennis Liotta	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Aaron Kantoff	Independent Director	less than a year	데이터 없음	데이터 없음
Samantha Truex	Independent Director	less than a year	데이터 없음	데이터 없음
Mitchell Chan	Independent Director	2.9yrs	US$60.12k	0% € 0

2.7yrs

평균 재임 기간

70yo

평균 연령

경험이 풍부한 이사회: C6K0 의 이사회는 경험(평균 재직 기간 2.7 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Avalo Therapeutics 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Avalo Therapeutics, Inc. Appoints Mittie Doyle as Chief Medical Officer

Avalo Therapeutics, Inc., Annual General Meeting, Aug 13, 2024

Avalo Therapeutics, Inc. Appoints Paul Varki as Chief Legal Officer

Avalo Therapeutics, Inc. Announces Board Appointments

Avalo Therapeutics, Inc., Annual General Meeting, Dec 05, 2023

Insider recently bought €52k worth of stock

Recent updates

Avalo Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Lotus Trial of Avtx-009 for the Treatment of Hidradenitis Suppurativa

Avalo Therapeutics, Inc. Appoints Mittie Doyle as Chief Medical Officer

Avalo Therapeutics Announces Active IND for AVTX-009, an Anti-IL-1ß mAb, to Treat Hidradenitis Suppurativa

Avalo Therapeutics, Inc., Annual General Meeting, Aug 13, 2024

Avalo Therapeutics, Inc. Appoints Paul Varki as Chief Legal Officer

Avalo Therapeutics Receives Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Stockholders' Equity Requirement

Avalo Therapeutics, Inc. Announces Board Appointments

Hearings Panel Grants Avalo Therapeutics an Exception from Compliance with the MVLS Rule and the Bid Price Rule and Extension of Continued Listing Until December 29, 2023

Avalo Therapeutics, Inc., Annual General Meeting, Dec 05, 2023

Nasdaq Determines to Delist Securities of Avalo Therapeutics

AUG Therapeutics, LLC entered into a purchase agreement to acquire rights, title and interest in, assets relating to AVTX-800 Series from Avalo Therapeutics, Inc. (NasdaqCM:AVTX).

Avalo Therapeutics, Inc. Receives Notice from Nasdaq Regarding Bid Price Rule

New major risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.59 loss per share (vs US$1.38 loss in 2Q 2022)

New minor risk - Insider selling

New major risk - Revenue and earnings growth

Avalo Announces Topline Data from Phase 2 Peak Trial for Avtx-002 (Quisovalimab) in Patients with Non-Eosinophilic Asthma

Insider recently bought €52k worth of stock

Insider recently bought €83k worth of stock

Insider recently bought €63k worth of stock

First quarter 2023 earnings released: US$0.85 loss per share (vs US$2.35 loss in 1Q 2022)

Insider recently bought €49k worth of stock

Insider recently bought €131k worth of stock

Full year 2022 earnings released

Avalo Therapeutics, Inc. has completed a Follow-on Equity Offering.

Avalo Therapeutics, Inc. has completed a Follow-on Equity Offering.

Avalo Therapeutics, Inc. Completes Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma

High number of new and inexperienced directors

Forecast to breakeven in 2024

Third quarter 2022 earnings released: EPS: US$0.34 (vs US$2.04 loss in 3Q 2021)

High number of new and inexperienced directors

Avalo Therapeutics, Inc. Advances B and T Lymphocyte Attenuator Agonist Fusion Protein (AVTX-008) to IND-Enabling Stage

Avalo Therapeutics Announces Board Changes

Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)

Avalo Therapeutics, Inc. Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.32 loss in 1Q 2021)

Avalo Therapeutics, Inc., Annual General Meeting, Jun 14, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Avalo Therapeutics, Inc. Announces Executive and Board Changes

Avalo Therapeutics, Inc. Announces Chief Executive Officer Changes

Avalo Therapeutics, Inc. Announces Resignation of H. Jeffrey Wilkins as Chief Medical Officer

Avalo Therapeutics, Inc. Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.16 loss in 3Q 2020)

Avalo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $27.5 million.

Avalo Therapeutics, Inc.(NasdaqCM:AVTX) dropped from NASDAQ Composite Index

Second quarter 2021 earnings released: US$0.88 loss per share (vs US$0.19 loss in 2Q 2020)

High number of new directors

Cerecor Inc. announced that it expects to receive $35 million in funding from Horizon Technology Finance Management, LLC

First quarter 2021 earnings released: US$0.32 loss per share (vs US$0.36 loss in 1Q 2020)

Forecast to breakeven in 2024

U.S. Food and Drug Administration Grants Fast Track Designation to CERC-002 of Cerecor Inc. for Treatment of Hospitalized Patients with COVID-19

Cerecor Inc. Doses First Patient in a Phase 1b Proof-of-Concept Clinical Trial of CERC-007 for the Treatment of Adult Onset Still’s Disease

Full year 2020 earnings released: US$0.88 loss per share (vs US$0.28 loss in FY 2019)

Revenue beats expectations

Cerecor Inc. Announces Final Efficacy Data Including 60-Day Mortality from Their Recently Completed Us-Based, Multi-Center (10 Sites)

Cerecor Inc. Appoints Schond L. Greenway as Chief Financial Officer

New 90-day high: €3.56

New 90-day high: €3.16

Cerecor Announces Fast Track Designation for CERC-803 for the Treatment of Leukocyte Adhesion Deficiency Type II

New 90-day high: €2.72

Cerecor Inc. Announces Successful Proof of Concept Data for CERC-002, a Unique LIGHT-Neutralizing Antibody, in Patients Hospitalized with COVID-19 ARDS

New 90-day high: €2.26

Cerecor Inc. Announces First Patient Dosed in A Phase 1B Clinical Trial of Cerc-007 for the Treatment of Relapsed or Refractory Multiple Myeloma

Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for Treatment of Relapsed or Refractory Multiple Myeloma

Cerecor Inc. Enters into an Amendment to Its Existing License and Supply Agreement with Watson Laboratories, Inc

Cerecor Inc. Appoints Gilla Kaplan, to Its Board of Directors

Cerecor Inc. Resumes Phase 1b Clinical Trial of CERC-002 for the Treatment of Severe Pediatric Onset Crohn’s Disease

CEO 보상 분석